Closing out their discussion on advanced RCC, expert hematologist/oncologists offer key takeaways from their discussion and look toward future treatment evolution in the first-line setting.
Videos
Shared insight on the data from the COSMIC-313 trial and the potential for first-line triplet regimens in patients with advanced clear cell renal cell carcinoma.
Sheela Tejwani, MD, highlights some exciting recent trial data and shares clinical pearls for community oncologists treating mCSPC.
An expert oncologist describes her approaches to treating patients with castration-sensitive prostate cancer and low-volume metastatic disease.
An expert oncologist describes her approaches to treating patients with castration-sensitive prostate cancer and low-volume metastatic disease.
Dr Tejwani lists the frontline treatment options currently available for mCSPC and reviews the chosen treatment regimen in the presented patient case.
Sheela Tejwani, MD, presents the case of an 83-year-old man with mCSPC, and shares her first impressions as compared to her typical patients.
Wesley Burkett, MD, adiscusses his excitement for the approval of pembrolizumab in combination with lenvatinib for patients with advanced endometrial carcinoma that is not microsatellite instability-high or mismatch repair deficient.
Glenn J. Hanna, MD, discusses proliferative leukoplakia and risk of oral cancer.
David O'Malley, MD, looks at the preclinical signals of the novel MUC16 antibody ubamatamab, which showed promising results for patients with recurrent ovarian cancer.
Frederick Marme, MD, discusses new results from the TROPICS-02 study of sacituzumab govitecan for the treatment of patients with hormone receptor-positive, HER2-negative metastatic breast cancer.
Moshe Ornstein, MD, MA, continues his discussion of I/O-TKI combination regimens by presenting data from the CheckMate 9ER trial.
Moshe Ornstein, MD, MA, shares data from the KEYNOTE-426 clinical trial that set a new standard of care for treatment-naïve metastatic clear cell RCC.
Naveen Pemmaraju, MD discusses the long-term results of the STML-401-0114 trial that demonstrated the benefits of tagraxofusp-ezrs as a monotherapy for patients with blastic plasmacytoid dendritic cell neoplasms.
Matthew P. Goetz, MD, discusses recent data on estrogen receptor mutations in patients with breast cancer.
Isabelle Ray-Coquard, MD, discusses the final overall survival results from the phase 3 PAOLA-1/ENGOT-ov25 trial.
Gene G. Finley, MD, explains a questions lingering on the benefit of immunotherapy in patients with small call lung cancer.
Panelists identify second-line treatment options they would consider in advanced clear cell RCC if a patient progresses following first-line therapy.
Expert hematologist/oncologists consider the potential role for adjuvant immunotherapy in patients with advanced clear cell renal cell carcinoma.
Nizar Tannir, MD, presents the case of a 57-year-old patient with intermediate-risk advanced clear cell RCC, and Scott Tykodi, MD, PhD, presents data from the CheckMate 214 trial.
Experts explain the treatment goals for patients with MDS, and discusses the role of molecular testing in patients with MDS.
Dr Eytan M Stein breaks down how patients with MDS are risk-stratified, and how the clinical outcomes differ between risk groups.
Jean Bourhis, MD, discusses results from the phase 2 study of xevinapant plus chemoradiation vs placebo and chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck.
Key opinion leaders discuss the options for patients with advanced clear cell RCC who have higher-risk metastatic disease.
Paul G. Richardson, MD, discusses what is expected and exciting for the future of multiple myeloma research.
Salman Fazal, MD, explains how to lower the risk of graft-versus-host disease in patients who undergo allogeneic stem cell transplant.
Cary Gross, MD, discusses the background of his research on patients with lung cancer and Medicaid.
Naval G. Daver, MD, discusses the latest research on magrolimab, a CD47 monoclonal antibody, for patients with acute myeloid leukemia and myelodysplastic syndrome.
Melissa M. Hardesty discusses the key takeaways of the phase 2 OVARIO study of a PARP inhibitor plus a VEGF inhibitor in women with advanced ovarian cancer as well as research still needs to examine in this space.
Ian W. Flinn, MD, PhD, discusses what factors go into his decision to use polatuzumab plus bendamustine and rituximab in certain patients with relapsed/refractory diffuse large B-cell lymphoma.